Advertisements

Pamol Infant

Quick links to important sections

Pamol Infant

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Pamol Infant

Quick Facts

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Form Oral solution (Liquid formulation)
Pharmacological Class Analgesic and Antipyretic
Common Purpose Symptomatic relief of pain and fever
Origin Synthetic (Para-aminophenol derivative)

What Type of Medicine is Pamol Infant?

Pamol Infant is a specialized medicinal preparation classified primarily as a non-opioid analgesic and an antipyretic, designed specifically for the pediatric population. The active constituent, Acetaminophen (Paracetamol), is chemically defined as a Para-aminophenol derivative, indicating its synthetic origin and distinct chemical structure. This classification reflects its use in managing common discomforts and fever across all age groups. Unlike products intended for adult consumption, this formulation is positioned specifically for use in infants and children, reflecting a focus on safe and appropriate dosing for the youngest patients.

Composition and Pharmaceutical Form

The core therapeutic component is the single active ingredient, Acetaminophen. To ensure appropriate and safe administration to young patients, the medicine is prepared as an oral solution—a liquid formulation intended for the oral route of administration. This form is necessary because it allows for simple administration and accurate measurement in patients who cannot swallow solid medicines. The preparation consists of the active drug suspended in an aqueous vehicle (liquid carrier). The use of a liquid form is intended for pediatric dosing, further establishing the practical application of this pharmaceutical form.

General Therapeutic Purpose and Benefit

The general function of the preparation aligns strictly with its pharmacological classification: to provide fundamental, symptomatic relief. As an analgesic, it assists in the management of pain sensation, and as an antipyretic, it helps the body lower an abnormally high temperature, a common occurrence during minor illnesses. The overall benefit is the improvement of the child's general comfort level by mitigating these two core, non-specific symptoms.

Regulatory References

  1. DailyMed Label for Acetaminophen Oral Solution
Advertisements

What side effects are possible with Pamol Infant?

Possible Side Effects and Safety Information

The safety profile for this medicine, which contains the active ingredient acetaminophen (paracetamol), is formally defined by government regulatory documents and is structured around the potential for adverse reactions in specific organ systems.

Category Description
Adverse reaction scope The primary safety focus is on dose-dependent hepatotoxicity (liver damage), with secondary concerns involving hypersensitivity reactions and hematological changes.
Frequency classification Many serious effects, such as agranulocytosis (blood system) and anaphylaxis (immune system), are classified as rare (affecting 1 to 10 users in 10,000) in official regulatory documents. Severe skin reactions are classified as very rare.
System-organ classes involved Officially documented effects are grouped by body system, including Hepatobiliary Disorders (liver), Blood and Lymphatic System Disorders, Immune System Disorders, and Skin and Subcutaneous Tissue Disorders.
Serious adverse reactions The most significant risks explicitly documented in regulatory sources are Severe Hepatotoxicity (acute liver failure), Anaphylactic Shock, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).
Population-specific safety The medicine is contraindicated in patients with severe hepatic impairment or active liver disease. Caution is advised for those with other risk factors, such as chronic malnutrition.
Safety-related limitations The key restriction is that the maximum total daily dose must not be exceeded from all sources due as the risk of severe liver damage is strictly dose-dependent.

The official regulatory safety profile is dominated by the constraint that dose limits must not be exceeded due to the serious, dose-dependent risk of hepatotoxicity, which is a major focus in all official documents. This structure ensures that potential serious adverse reactions, including severe skin disorders and anaphylaxis, are highlighted alongside special safety considerations for patients with existing hepatic impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory documentation for Acetaminophen (Paracetamol) overdose is focused on the time-critical need for intervention due to the potential for delayed, severe organ damage.

Mandatory Emergency Action

Immediate medical attention must be sought for any suspected overdose, even in the absence of initial symptoms. Urgent hospitalization is required for assessment and time-sensitive treatment. Individuals must provide the product name and the time of ingestion to emergency services.

Documented Overdose Manifestations

Classification Official Regulatory Statement
Initial Symptoms May include non-specific signs such as nausea, vomiting, anorexia, diaphoresis (sweating), and general malaise.
Severe Outcomes The progression of toxicity can lead to hepatic necrosis, acute hepatic failure, and renal tubular necrosis. Severe complications include hepatic encephalopathy and coma, which carry the risk of death.

Required Interventions and Monitoring

  • The official, specific antidote is N-acetylcysteine (NAC).
  • Management procedures include the mandatory monitoring of Plasma Acetaminophen Concentration and repeated assessment of Liver Function Tests (LFTs) and Prothrombin Time (PT)/INR to track the extent of injury.
  • Individuals with pre-existing hepatic impairment, chronic alcoholism, or malnutrition are officially documented to have an increased risk of severe hepatotoxicity following an overdose.

The profile emphasizes that intervention must occur rapidly due to the latency of the most severe clinical manifestations.

Advertisements

Therapeutic Uses of Pamol Infant

Pamol Infant generally provides focused, symptomatic relief and is commonly used to help with symptoms related to physical discomfort and symptoms related to systemic imbalance, which are often present during acute pediatric illness. It is applied in addressing conditions associated with acute or disruptive episodes, particularly in infants and children. As such, the medication is commonly used to address pain and fever, which are frequent sources of acute discomfort in children.


Symptomatic Management of Pain and Fever

The medicine is relevant for easing symptoms that interfere with daily functioning, primarily fever (pyrexia) and mild-to-moderate pain. It is applied across domains where additional symptomatic support is needed, such as for headaches, general aches, and fever that may follow immunisation. The primary benefit provides support that helps ease the overall symptom burden and assists with lowering the fever.


Supporting Comfort in Acute Pediatric Scenarios

The preparation is commonly used across conditions presenting with acute episodes, including teething pain and discomfort associated with common colds. Applied during phases of increased distress or discomfort, this support contributes to improved comfort during periods of heightened symptoms by addressing symptom clusters that may become intense or disruptive. The medication may help patients cope more steadily with symptom fluctuations when symptoms become more noticeable.


Quick Fact: Relief for Symptoms related to Systemic Imbalance and Symptoms related to Physical Discomfort

Regulatory References

  1. MedlinePlus Medical Encyclopedia
Advertisements

Eligibility and Restrictions for Use

Pamol Infant is licensed primarily for use in infants and children. Official regulatory documents define eligibility across several key populations.

Contraindicated Populations

The medicine is strictly contraindicated and must not be used in patients with known hypersensitivity to paracetamol or any of the product's excipients. It is also prohibited for patients diagnosed with severe hepatic impairment or severe active liver disease.

Age-Related Eligibility

The medicine is generally approved for children aged 3 months and older. Use is not recommended in pre-term newborn infants due to insufficient data. Infants aged 2 to 3 months may only use the product under medical direction, typically restricted to short-term use for post-immunisation fever.

Conditional and Restricted Use

Use requires caution in patients with severe renal impairment or non-severe hepatic impairment. The label also specifies caution for populations at risk of glutathione depletion, such as those with chronic malnutrition or chronic alcoholism. For pregnancy and lactation, the use of the active ingredient is generally permitted only when clinically indicated and must be used at the lowest effective dose for the shortest duration.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of the active ingredient, Acetaminophen (Paracetamol), is documented by regulatory authorities, focusing on pharmacokinetic alterations and increased risk of hepatotoxicity.

Documented Interaction Patterns

Interaction Type Interacting Substance(s) Official Regulatory Outcome
Hepatotoxic Risk Chronic, Excessive Alcohol; Other Acetaminophen Products Formal warnings against co-administration due to significantly increased risk of severe liver damage.
Clearance Reduction Probenecid Documented reduction in acetaminophen clearance, leading to increased plasma concentrations of the drug.
Absorption Rate Metoclopramide, Domperidone Accelerate the rate and speed of absorption.
Anticoagulant Effect Warfarin (Vitamin K Antagonists) Enhanced anticoagulant effect (increased bleeding risk) with prolonged, regular use.
Metabolic Risk Enzyme Inducers (e.g., Phenytoin, Rifampicin) May increase the formation of potentially toxic metabolites.

Administration Timing Constraints

The regulatory label for Cholestyramine requires specific administration timing. Acetaminophen must be taken at least 1 hour before or 4 hours after Cholestyramine administration to mitigate the documented reduction in acetaminophen absorption.

Population-Specific Notes

The hazard of toxicity is formally documented as greater in individuals with chronic excessive alcohol consumption due classifying this as a significant interaction-related restriction.

Advertisements

Mechanism of Action

Central Control of the Thermoregulatory Set Point

The mechanism for modulating core temperature begins with the selective inhibition of cyclooxygenase (COX) enzymes found predominantly in the hypothalamus, the brain region controlling core temperature. Acetaminophen acts as a reducing agent on this enzyme, which prevents the synthesis of Prostaglandin E₂ (PGE₂)—the key mediator that signals the change in the hypothalamic temperature set point. The resulting reduction in central PGE₂ production directly lowers this elevated set point, initiating physiological heat-loss mechanisms, which adjust core body temperature.


Multimodal Modulation of Pain Pathways

The mechanism for dampening nociceptive signals is achieved through a multimodal process that influences the body's natural signaling systems. This mechanism involves the drug’s metabolite, AM404, which activates TRPV1 receptors and functionally modulates the CB₁ receptor system in the Central Nervous System (spinal cord and brainstem). This molecular action reinforces the descending pain-inhibitory signals, increasing the pain threshold and thereby reducing the central transmission of nociceptive signals.


Mechanistic Constraint: Lack of Anti-Inflammatory Action

The mechanism of Acetaminophen is highly constrained by the biochemical environment of the tissue. Because its COX inhibition is ineffective in the high-peroxide, oxidative state of peripheral inflamed tissues, the drug does not reduce local PGE₂ levels at the site of injury. This functional constraint means the drug's mechanism prevents the drug from altering local eicosanoid levels or associated tissue responses.

Advertisements

Dosage and Administration Information

Administration Guidelines

Pamol Infant is an oral solution that is administered exclusively via the oral route. Use is structured around precise weight-based calculations and strict time constraints to ensure appropriate pediatric dosing.

The standard single dose is based on the child’s body weight, typically set between 10 and 15 mg per kilogram. To prevent measurement errors, the prescribed volume of the solution must be measured accurately using the dosing device (syringe or spoon) supplied with the product. Furthermore, the bottle must be shaken thoroughly for at least ten seconds before any measurement is taken to ensure uniform concentration of the active ingredient.


Dosing Frequency and Limits

The correct administration schedule requires a minimum interval of four hours between any two doses. The total number of doses administered is limited, with a maximum of four to five doses allowed within a 24-hour period. Use is constrained by a maximum duration of three consecutive days without guidance from a healthcare professional.


Population and Procedural Restrictions

This product is not intended for general use in infants under two months of age. Specific, limited dosing regimens exist for infants aged two to three months following a vaccination. A critical procedural constraint is the absolute prohibition against administering the solution concurrently with any other product that contains paracetamol or acetaminophen.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence for Paracetamol in Infants

Pamol Infant contains paracetamol (acetaminophen), which is widely researched and used as a first-line agent for managing fever (antipyresis) and mild-to-moderate pain (analgesia) in the pediatric population, including infants from birth.

Efficacy and Analgesic Studies

Studies consistently report that paracetamol, when used at generally recommended doses (e.g., 15 mg/kg), is associated with a greater reduction in temperature and pain perception compared to placebo. It is often evaluated against non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen in randomized trials for short-term fever and pain management.

Evidence from comparative trials suggests that paracetamol's efficacy for reducing fever and pain in children is comparable to that of ibuprofen, particularly when appropriate dosing schedules are maintained.

Study Focus Key Finding (In Context)
Antipyresis Paracetamol may support a more consistent temperature reduction when multiple doses are administered over time.
Pain Relief Paracetamol is investigated as part of multimodal strategies, including post-operative care, and may contribute to reduced need for other pain medications (opioid-sparing effects).

Safety and Tolerability Profile

Long-standing clinical evidence supports a generally favorable short-term tolerability profile for paracetamol when administered at therapeutic doses. Adverse events are rare and typically mild, such as gastrointestinal upset.

Recent safety reviews and cohort studies emphasize the importance of using the correct dose based on the infant's weight to prevent severe complications, particularly hepatotoxicity (liver damage), which is a known risk of overdose. Research continues to monitor the potential long-term safety of early life exposure to paracetamol, including associations with neurodevelopmental and atopic outcomes; however, these findings are often limited by observational design and do not currently demonstrate causation.

Key Studies & References

  1. Long-term safety of paracetamol use in infancy: a systematic review of neurodevelopmental and atopic outcomes
  2. Acetaminophen Dosing and Risk of Liver Injury in Children: A Safety Assessment (Hepatotoxicity Studies)
  3. National Institute for Health and Care Excellence (NICE) Guideline for Fever in under 5s: assessment and initial management
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pamol Infant (FAQ)


Q: How quickly should I expect Pamol Infant to start working?

According to regulatory data, the active ingredient in Pamol Infant generally achieves its maximum concentration in the bloodstream approximately 30 to 60 minutes after being taken by mouth. This period indicates the typical onset time for the effects of the medicine to begin.


Q: How long does the effect of Pamol Infant typically last?

Official administration guidelines structure the use of the medicine around time-based constraints. These instructions state that a minimum interval of four hours must be maintained between any two doses, reflecting the required time constraint for repeated administration.


Q: Does Pamol Infant cause drowsiness in infants?

Drowsiness is not categorized as a common side effect of the medicine in infants, according to regulatory summaries. However, official documents note that it is reported as a potential symptom in the context of a rare, severe complication called metabolic acidosis, which has been associated with prolonged use.


Q: Are there common side effects of Pamol Infant that parents often mention?

Official product information indicates that some minor and typically mild adverse events can occur. These may include short-term upset stomach or throwing up. Furthermore, the inactive ingredient Sorbitol may occasionally lead to temporary gastrointestinal discomfort.


Q: Is Pamol Infant suitable for newborns or only older infants?

Dosing regimens for the active ingredient do exist for the earliest life stages, including neonates. However, official product labeling indicates that use for children under two years of age typically requires consultation with a healthcare professional.


Q: Is a rash a known side effect listed for Pamol Infant?

A skin rash is a documented side effect that may signify a hypersensitivity or allergic reaction to the medicine. Official safety information also documents the risk of rare, very severe skin reactions, such as Stevens-Johnson Syndrome.


Q: What happens if a child takes Pamol Infant close to another medication?

Regulatory sources generally indicate that the medicine can be used concurrently with most common prescription medications. However, the active ingredient is described as interacting with specific classes of drugs, such as certain blood thinners or enzyme-inducing medications. Official resources contain a full list of documented interactions.


Q: If a child has a health condition, are there any general cautions about using Pamol Infant?

Official safety documentation advises caution for patients who have pre-existing health conditions. These cautions specifically apply to infants with certain forms of kidney problems or non-severe liver impairment.


Q: Is Pamol Infant known to affect a child's stomach?

Minor side effects like upset stomach or throwing up are listed in the official safety profile. Additionally, the inactive ingredient Sorbitol, which is a sugar alcohol, may sometimes cause general gastrointestinal discomfort or a mild laxative effect.


Q: Can infants with kidney issues use Pamol Infant?

Official information advises caution for patients diagnosed with severe renal impairment, which refers to significant kidney problems. In such specific cases, regulatory guidelines state that the dosing frequency may require adjustment to prevent accumulation of the drug.


Q: Does the official information state Pamol Infant affects vaccinations?

Official guidance notes that a specific regimen exists for the short-term use of the medicine following immunisation. Furthermore, some regulatory guidance includes advice regarding avoiding administration of the active ingredient before a child's vaccination.


Q: Is Pamol Infant the same as other pain relievers I see in the pharmacy?

The medicine is officially classified as a non-opioid analgesic (pain reliever) and an antipyretic (fever reducer). This classification indicates that its mechanism of action is distinct from other classes of pain relief, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Q: Why is the concentration of Pamol Infant different from the adult version?

The product's concentration is prepared specifically for pediatric dosing. This difference reflects the regulatory need for precise, weight-based calculations for infants to ensure effective treatment while strictly mitigating the risk of accidental overdose.


Q: Can Pamol Infant be used if a child is already taking antibiotics?

Official sources generally describe the active ingredient as compatible with most common prescription medications, including antibiotics. However, it is noted that a small number of specific antibiotics may increase the risk of forming potentially toxic metabolites.


Q: Does the medicine come in different flavors for infants?

Yes, the liquid solution is formulated with inactive ingredients that provide both color and flavor. This is done to make the medicine palatable and acceptable for infants and children during administration.


Q: Is Pamol Infant safe to give to an infant who has asthma?

The product is not considered contraindicated for use in infants who have asthma. Clinical evidence suggests the use of the active ingredient during respiratory illness is generally tolerated without increasing the risk of asthma flare-ups.


Q: What are the ingredients that help with taste in Pamol Infant?

According to official formulation information, the inactive ingredients include specific flavorings (such as cherry) and sweeteners. Common sweeteners often found in these products include Sucrose (sugar) and Sorbitol (a sugar alcohol).


Q: Does Pamol Infant come with a specific measuring tool?

Regulatory guidance requires that a dedicated dosing device be provided with the product. Official documentation requires that only the specific device provided with the package be used for measurement to ensure accuracy.


Q: Does the package insert for Pamol Infant mention any specific warnings?

Regulatory documents and package inserts include significant warnings focusing on the safe use of the product. The most critical warning concerns the risk of severe liver damage that can occur if the maximum total daily dose is exceeded.


Q: What is the purpose of the liquid form versus a suppository, if available?

The liquid oral solution is intended to allow for simple administration and accurate measurement via the mouth. Other forms, such as rectal suppositories, may be officially indicated for situations where administration by mouth is not possible.


Q: What information is provided about potential overdose symptoms?

Official information provides details on potential symptoms of overdose, which may appear within the first 24 hours. These symptoms can include paleness, sweating, vomiting, loss of appetite, and abdominal pain. Overdose can lead to severe liver damage, and is officially described as a situation requiring immediate medical evaluation.


Q: Is Pamol Infant considered a first-line treatment for infant fever?

The active ingredient in Pamol Infant is widely categorized by major health organizations as a first-line therapy option for managing pain and fever in pediatric populations. This positioning is supported by extensive clinical evidence.


Q: What age range is 'Infant' referring to in the product name?

In clinical contexts, the term 'infant' often refers to the age range from 29 days up to 2 years. Product eligibility may extend beyond or be restricted within this range, and should be confirmed using the specific package insert provided with the medicine.


Q: Does Pamol Infant contain any alcohol or sugar substitutes?

Many oral solution formulations are explicitly labeled as being Alcohol Free. Common inactive ingredients often include the sweeteners Sorbitol (which is a sugar alcohol) and Sucrose (table sugar).


Q: Are there certain components in Pamol Infant that are known allergens?

Official product information details inactive ingredients that may cause allergic reactions, even if rarely. These can include certain colorants and preservatives, such as Tartrazine, Carmoisine, and Parahydroxybenzoates.

Advertisements

How should Pamol Infant be stored and disposed of?

How to Store and Dispose of Pamol Infant

Pamol Infant (Paracetamol oral solution) must be stored strictly according to official regulatory labeling to ensure stability and safety.


Required Storage Conditions

Temperature and Light: Store the product at a temperature not exceeding 25 C or 30 C and protect from light. Do not under any circumstances refrigerate or freeze the solution. The medicine must be kept in its original container.

Child Safety: The product must be stored out of the sight and reach of children.

Stability: Some formulations have an in-use limit, such as a maximum of six months after first opening, provided all storage conditions are maintained.


Official Disposal Rules

Unused or expired Pamol Infant must not be disposed of via wastewater or household waste. Disposal must be performed in accordance with local requirements for unused medicines, typically by consulting a pharmacist or utilizing an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pamol Infant found in:

A-Z Index: